Lequin Rudolf M
Diagnostics Consultancy Desk, Eindhoven, The Netherlands.
Clin Chem. 2005 Dec;51(12):2415-8. doi: 10.1373/clinchem.2005.051532. Epub 2005 Sep 22.
This brief note addresses the historical background of the invention of the enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA). These assays were developed independently and simultaneously by the research group of Peter Perlmann and Eva Engvall at Stockholm University in Sweden and by the research group of Anton Schuurs and Bauke van Weemen in The Netherlands. Today, fully automated instruments in medical laboratories around the world use the immunoassay principle with an enzyme as the reporter label for routine measurements of innumerable analytes in patient samples. The impact of EIA/ELISA is reflected in the overwhelmingly large number of times it has appeared as a keyword in the literature since the 1970s. Clinicians and their patients, medical laboratories, in vitro diagnostics manufacturers, and worldwide healthcare systems owe much to these four inventors.
本短文介绍了酶免疫测定法(EIA)和酶联免疫吸附测定法(ELISA)发明的历史背景。这些测定法是由瑞典斯德哥尔摩大学的彼得·佩尔曼(Peter Perlmann)和伊娃·恩格瓦尔(Eva Engvall)研究小组以及荷兰的安东·舒尔斯(Anton Schuurs)和鲍克·范·韦门(Bauke van Weemen)研究小组独立且同时开发的。如今,世界各地医学实验室中的全自动仪器都采用免疫测定原理,以酶作为报告标记物,对患者样本中的无数分析物进行常规检测。自20世纪70年代以来,EIA/ELISA作为文献中的关键词出现的次数多得惊人,这反映了它的影响力。临床医生及其患者、医学实验室、体外诊断制造商以及全球医疗保健系统都非常感激这四位发明者。